Aspirin's Target, The COX-2 Enzyme, Linked To Cancer Of The Uterus

[Guest guest]

Source:   University Of Illinois At Chicago (http://www.uic.edu/)

Date:   Posted 7/18/2002

Aspirin's Target, The COX-2 Enzyme, Linked To Cancer Of The Uterus

A researcher at the University of Illinois at Chicago College of Medicine

has discovered a link between cancer of the uterus and the COX-2 enzyme, a

compound first implicated in the painful inflammation associated with

arthritis and more recently in the spread of colon cancer.

Nationally, cancer of the uterus is the most common cancer of the female

reproductive system, accounting for 6 percent of all cancers in U.S. women.

In a laboratory study, Dr. Serdar Bulun, director of reproductive

endocrinology and infertility and a member of the UIC Cancer Center,

cultured malignant epithelial cells from the lining of the uterus alongside

normal cells from the same kind of tissue.

In the interaction between normal and malignant cells, the malignant tissue

induced the normal tissue to increase production of the enzyme

cyclooxydase-2 (COX-2). Levels of certain prostaglandins also rose,

hormone-like substances synthesized by COX-2.

As Bulun and other researchers have shown, COX-2 and its product

prostaglandins set off a cascade of molecular events, including an abnormal

increase in estrogen, that leads to tumor growth.

" The findings suggest that everyday drugs like aspirin or ibuprofen --

nonsteroidal anti-inflammatory drugs that block the COX-2 enzyme -- might be

tried as treatments for uterine cancer in combination with other therapies, "

Bulun said.

Results of the study will be published in the July 17 issue of the Journal

of Biological Chemistry.

The prostaglandins synthesized by COX-2 are mediators of inflammation, the

body's response to injury characterized by increased blood flow to the

tissue, increased temperature, redness, accumulation of immune cells and

pain.

Bulun has found increased levels of COX-2 and its product prostaglandins in

endometriosis, a painful, inflammatory disease in which endometrial tissue

from the lining of the uterus attaches to other organs, including the

ovaries, fallopian tubes, and sometimes the gut and rectum, causing internal

bleeding, chronic pelvic pain and even infertility.

COX-2 and prostaglandins are also involved in the spread of tumors, such as

in colon cancer. They reduce the rate of cell death, increase the

invasiveness of the malignancies and promote the growth of blood vessels

that deliver nourishment to the lesions. Currently, drugs that inhibit COX-2

are prescribed in the treatment of precancerous polyps in the colon and

colon cancer, where cells have increased levels of the enzyme.

In previous research, Bulun found that the prostaglandins manufactured by

COX-2 stimulate the production of estrogen. Cancer of the uterus, as well as

certain kinds of breast cancer and endometriosis, depends on estrogen for

fuel, and estrogen itself drives the manufacture of prostaglandins.

" You see how crafty this cancer is, " Bulun said. " By encouraging the

production of COX-2, it sets in motion a continuous cycle whereby the tumor

can thrive and grow. "

In two additional articles published in the July issue of the Journal of

Clinical Endocrinology and Metabolism, Bulun demonstrates that two other

molecules also increase production of COX-2. One molecule, called vascular

endothelial growth factor, is involved in promoting the growth of blood

vessels that feed the growing pathological tissue. The other molecule,

interleukin-1beta, is a small molecule associated with the immune system,

which deploys cells to sites where foreign tissue has invaded.

" These findings suggest that cancer of the uterus finds multiple ways of

ensuring its survival, " Bulun said.

For more information about the UIC Cancer Center, see

http://www.uic.edu/com/cancer.

For more information about UIC, see http://www.uic.edu